Free Newsletter
ALSO NOTED: Novartis may hand out cancer drug in Thailand; Abilify gets new use against major depression;
> Novartis may give Thailand free cancer meds if the country lays off its fight to compel drug makers to license generic versions of patented remedies. Report
> Bristol-Myers Squibb's antipsychotic med Abilify got the FDA's nod as an add-on therapy for major depression in patients who don't respond fully to antidepressants alone. Report
> Datamonitor predicts that sales of the Bayer/Onyx drug Nexavar will be "substantially boosted" by its new U.S. approval for treatment of inoperable liver cancer. Report
> Canadian students are abusing prescription painkillers at an unprecedented rate, according to a new survey. Report
And Finally... Need more evidence that stress can be a killer? The stress hormone norepinephrine appear to stimulate tumor-cell growth. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: